TCM
CLDX icon

Tang Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Tang Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,192
Closed -$945K – 111
2022
Q4 		$945K Sell
21,192
-139,027
-87% -$4.96M 0.14% 68
2022
Q3 		$4.5M Buy
+160,219
New +$4.91M 0.55% 43
2016
Q3 		– Sell
-3,333
Closed -$220K – 10
2016
Q2 		$220K Hold
3,333
– – 0.1% 12
2016
Q1 		$189K Buy
+3,333
New +$375K 0.09% 15

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Tang Capital Management's CLDX Position: Q1 2023 in Review

Tang Capital Management sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 21,192 shares — an estimated $945K sold.

Tang Capital Management first reported a position in CLDX in Q1 2016 and held it in 4 quarters. The position peaked at $4.5M in Q3 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • Tang Capital Management reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Tang Capital Management sold 21,192 Celldex Therapeutics shares in Q1 2023, an estimated $945K.
  • Tang Capital Management first reported a position in Celldex Therapeutics in Q1 2016 and held it in 4 quarters.
  • Tang Capital Management's Celldex Therapeutics position peaked at $4.5M in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Tang Capital Management's 13F filing for Q1 2023, filed 15 May 2023.